Scleroderma: the skin that tightens, the Raynaud's that comes first, and the organ watch that matters most
Last updated September 3, 2026.
Scleroderma, systemic sclerosis, is an autoimmune condition in which the body makes too much collagen, so the skin tightens and thickens, and, in the systemic forms, the same process can affect the blood vessels and the internal organs, the gut, the lungs, the heart, and the kidneys. It is rare, it is commoner in women, and its first sign is usually Raynaud's, the fingers going white and blue in the cold, often years before anything else. The condition runs on a wide spectrum: the limited kind tends to stay in the fingers, hands, and face with slow internal involvement, while the diffuse kind tightens skin more widely and faster with earlier organ involvement, and the antibody tests help sort which track a person is on. There is no cure, and the management is two things done well: treating each piece, the Raynaud's, the reflux, the skin, the blood pressure, and monitoring the organs on a schedule, because the two complications that matter most, lung scarring and a sudden kidney crisis, are both far more treatable caught early. The worth-knowing parts: the ACE-inhibitor kidney protection works so well that the kidney crisis, once the great fear, is now usually managed; the lung checks, breathing tests and scans, are the appointments never to skip; the tight skin and the stiff fingers respond to physiotherapy and occupational therapy more than to any cream; and the fatigue and the changed appearance deserve the same honest management as the organs.
What does it look like?
Raynaud's first, usually: fingers going white then blue then red in the cold. Then the skin: tight, shiny fingers, puffiness of the hands, the face tightening, small mouth. The common companions: severe reflux, the gut slowing, the fingertips ulcerating or developing small calcium deposits, and the fatigue. The organ chapter arrives differently in each form: the lung scarring, the pulmonary blood pressure rise, and the kidney crisis are the watched-for complications.
Why does it happen?
The immune system drives the cells that make collagen into overproduction, and the excess collagen thickens the skin and can stiffen the walls of small blood vessels and internal organs. Why it starts is unknown; it is not inherited in any simple way, it is commoner in women, and certain exposures, silica dust above all, raise the risk. It is not contagious and it is not caused by anything the patient did.
How is it treated?
- Each piece gets its own treatment. Raynaud's gets vessel-widening medicines and serious cold protection; the reflux gets acid suppression; the skin and stiff fingers get physiotherapy and occupational therapy; the itch and tightness get their own care.
- The organs get monitored on a schedule. Breathing tests, lung scans, heart and lung-pressure checks, blood pressure and kidney blood tests: the schedule exists because the serious complications are treatable caught early, and some arrive silently.
- Immune-suppressing medicines for the active forms. For diffuse skin disease or lung involvement, medicines that damp the immune system slow the process, and the options have expanded in recent years.
- The kidney crisis has an effective defense. ACE inhibitors, started fast, transformed the once-feared kidney crisis into a usually-manageable event, which is why home blood pressure monitoring matters in the early diffuse years.
When does it need urgent review?
A sudden rise in home blood pressure readings, new breathlessness, a finger ulcer that turns black or refuses to heal, or a sudden drop in urine earns same-day advice. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
I read I might only have ten years. Is that true?
No, and the sentence you read is describing a different era of this disease. The old survival statistics come from before the monitoring machinery existed: the complications that used to do the damage, the kidney crisis and the lung scarring, are now screened for, caught early, and treated, and the kidney crisis in particular has been transformed by one class of blood pressure medicine into a usually-manageable event. Most people with systemic sclerosis live for decades, the range is wide, and the limited form often runs a slow, manageable course. Your own outlook depends on your version, the antibodies, the organ checks, the skin score, and that picture will sharpen over your first year of monitoring. The websites are not lying; they are dated, and the monitoring schedule you have just been handed is exactly the reason they are dated.
What does all the monitoring actually catch?
It catches the serious complications while they are still treatable, which is the entire point. The breathing tests and lung scans watch for lung scarring, which responds to treatment caught early. The heart and lung-pressure checks watch for the pulmonary pressure rise, which arrives silently and has effective treatments now. The kidney blood tests and the home blood pressure readings watch for the kidney crisis, which announces through a sudden pressure rise and is stopped by fast ACE-inhibitor treatment, the single biggest success story in this condition. And the skin score tracks the collagen process itself, steering the immune-suppression decisions. None of it is surveillance for its own sake: every appointment on the schedule maps to a complication that is dangerous late and manageable early, and showing up is treatment.
Is there anything that slows the disease itself, or is it all symptom management?
There is, and the options have expanded in the last decade. The immune-suppressing medicines, used for the diffuse skin form and for lung involvement, slow the collagen overproduction itself rather than just treating its effects, and the evidence for them in the right patients is solid. Alongside those, the per-piece treatments are not nothing: the vessel-widening medicines protect the fingers' circulation, the acid suppression protects the esophagus, and the physiotherapy keeps the hands working, and the cumulative effect of all of it is a disease managed rather than endured. The honest frame: scleroderma is not yet a curable condition, but it is a treatable one, and the difference between treated and untreated is the difference the old websites never show.
My fingers are tightening. Will I lose the use of my hands?
The hands are the place where your own effort has the most leverage, and the physiotherapy is the lever. The tightening comes from collagen in the skin and the tendons, and left alone it stiffens the fingers toward a curl, but the hand therapy, stretching, wax baths, the exercises done daily, keeps the range measurably better, and the occupational therapy solves the practical problems the stiffness creates. The fingertip ulcers that sometimes come with the Raynaud's get their own aggressive treatment, because they are the place the circulation matters most. The honest expectation: most people keep functional hands, the stiffness is managed rather than reversed, and the ones who do best are the ones who treat the exercises like medicine, because in this condition they are.
What should I actually change in daily life?
The list is practical and most of it is about warmth and energy. Cold is the enemy: the Raynaud's rule is keep the whole body warm, not just the hands, because the reflex is driven by core temperature, and gloves, layers, and pre-warmed everything become normal. Skin: moisturize daily, protect the fingertips, and treat any break in the skin early. Eating: smaller meals, the reflux rules, and the team dietitian if the gut slows. Energy: pace, because the fatigue is real and planning beats pushing, and a business owner learns to spend energy like capital. Smoking, if it is anywhere in the picture, ends: it hits the exact vessels this condition attacks. And the monitoring: home blood pressure readings as directed, because in the early years that simple number is the kidney's early-warning line.
Will my children get this?
Almost certainly not, and the genetics are worth saying plainly: scleroderma is not inherited in any simple way. It does run very loosely in families, the relatives of someone with it carry a slightly higher chance of an autoimmune condition of some kind, but the actual risk of a child developing scleroderma itself remains very small, and there is no test to run and nothing to screen them for. What is worth passing on when they are older is the awareness: a child who knows their parent has an autoimmune condition mentions the family history at appointments, and that is the whole inheritance in practice. Your energy is better spent on the monitoring and the hands than on this particular worry, and the team will tell you the same.